Collaborative and Other Relationships (Details 6) (ISIS Pharmaceuticals, USD $) In Millions, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
ISIS Pharmaceuticals
Collaborative arrangements and non-collaborative arrangement transactions
Total upfront and milestone payments made to collaborative partner	$ 71.0
Expense Incurred By Collaboration	0.6	0	0
Total expense reflected within our consolidated statements of income	0.6	0	0
Development Expense Incurred By Collaboration Excluding Upfront And Milestone Payments	0.6
Estimate of additional amounts to be incurred by us in Product development	$ 697.6